Although nanodiamonds have long being considered as a potential tool for biomedical research, the practical in vivo application of nanodiamonds remains relatively unexplored. In this paper, we present the first application of in vivo MRI contrast enhancement using only iron embedded magnetic nanodiamonds. MR image enhancement was clearly demonstrated in the rendering of T2-weighted images of mice obtained using an unmodified commercial MRI scanner. The excellent contrast obtained using these nanodiamonds opens the door to the non-invasive in vivo tracking of NDs and image enhancement. In the future, one can apply these magnetic nanodiamonds together with surface modifications to facilitate drug delivery, targeted therapy, localized thermal treatment, and diagnostic imaging.
Introduction
Nanodiamonds (NDs) are highly valued for use in a variety of fields, such as lubricant additives 1 , electronics devices for energy harvesting 2 , slow-neutron reflectors 3 , and biomedical applications 4, 5 . The outstanding bio-compatibility of NDs make them ideal for drug delivery 6 , anticancer therapy 7 , tooth and bone implants 8 , antimicrobial agents 9 and labeling 10 . ND labeling applications can be divided into two main categories: light-based methods (e.g., fluorescence imaging 11 , near-infrared imaging 12 , and photoacoustic imaging 13 ) and magnetic resonance imaging [14] [15] [16] [17] (MRI). When using light-based methods, defects within the diamond facilitate the emission of light and in so doing overcome many of the difficulties involved in detection. More than one hundred types of diamond defect have been identified 18 , covering the entire visible spectrum. The most well-known defects are the silicon vacancy center and the nitrogen vacancy (NV) center, which produce emissions in the red region (600 ~ 800 nm), making them highly visible in fluorescence microscopy 19 . Unlike chemical dyes, the fluorescence of diamonds does not diminish over time, which makes them ideal for experiments of extended duration. In a previous paper, we presented iron embedded magnetic NDs associated with NV centers, which are compatible with existing fluorescence observation technology as a potential dual functional in vivo tracer 20 .
Nonetheless, the in vivo imaging of NDs is still limited to regions that are optically accessible, i.e., only few centimeters from the surface. Imaging deep within the body requires MRI.
The ability to differentiate between normal and tumor tissue makes MRI a powerful diagnostic tool. Furthermore, MRI is noninvasive. Nonetheless, obtaining reliable images depends on the use of contrast agents. Two ND-based methods have been developed to enhance the contrast of MRI images. The first method involves attaching magnetic elements 17, 21 (Gd or Mn complex) to the surface of NDs. The second method involves hyperpolarizing the NDs via the Overhauser effect 16 . Unfortunately, both of these methods necessitate complex chemical synthesis processes or specially designed ultra-low magnetic field MRI scanners. At present, there is a notable lack of research on in vivo MRI contrast enhancement methods using only NDs. In fact, the in vivo use of NDs is rare.
Ion implantation is a mature technology, which has been used in the semiconductor industry for more than 50 years 22 . This method involves the insertion of atoms directly into the diamond lattice to enhance their functionality. In a previous paper, we sought to eliminate the need for conventional chemical methods by fabricating iron embedded magnetic NDs with great bio-compatibility via ion implantation 15, 23 . In this paper, we present iron embedded magnetic NDs for use as an MRI contrast agent at room temperature with an existing commercial MRI scanner. In vivo experiments demonstrate that the proposed iron embedded magnetic NDs are indeed nontoxic and useful, thereby opening the door on the noninvasive tracking of NDs and the immense possibilities that this brings.
Results and Discussions
In a previous paper, we illustrated the efficacy of iron embedded magnetic NDs (FeNDs) for the in vitro enhancement of contrast in MRI images 15 . More advanced in vivo experiments require the dispersion of Fe-NDs in physiological solutions for injection into animals. Unfortunately, nanoparticles are highly susceptible to aggregation in physiological solutions 24 , which greatly increases the risk of side-effects. The use of albumin to facilitate the dispersion of nanoparticles in physiological solutions is wellestablished 25 . Bovine serum albumin (BSA) has proven innocuous for mice 25 ; therefore, we adopted BSA for the surface treatment and produced four samples: pure NDs, FeNDs, NDs/BSA conjugates, and Fe-NDs/BSA conjugates. Dynamic light scattering (DLS) was used to measure the particle size distribution and zeta potential. signal intensity from the leg area will become brighter after injection. We observed an obvious reduction in signal intensity in the area injected with Fe-NDs, indicating negative contrast enhancement. The untreated NDs did not produce obvious negative contrast enhancement. The success of contrast enhancement and the fact that the mice remained healthy and strong after the experiments prompted us to perform more advanced in vivo tests.
Previous research exploring the biodistribution of NDs revealed that the injected
NDs collect in the liver and remain there for a short period of time 25, 27 . In our previous FTIR tests, there was no significant difference between the Fe-NDs and NDs in terms of surface profile, which suggests that the biodistribution is probably the same. We expected that the magnetic Fe-NDs would accumulate in the liver causing local inhomogeneities in the magnetic field, and this was the case in the experiments. Water protons in the liver were dephased by inhomogeneity in the magnetic field and the T2 was shortened by additional spin-spin interactions. This led to a decrease in the signal intensity from the liver, resulting in a darker image, thereby physically confirming the contrast enhancement capability of Fe-NDs.
In this work, intraperitoneal injection was used to observe negative contrast enhancement in the mice liver because it was very difficult for us to perform intravenous injection on mice. We initially intended to follow a protocol described in the literature 27 in which the dose required for visualization is achieved through multiple intraperitoneal injections. Unfortunately, we were unable to secure the use of the MRI to perform scanning after each injection; therefore, we had to complete the in vivo experiments using a single high-dose injection. In the first round of experiments, we obtained T2-weighted mice MR images prior to injection, and then at one day and five days after injection. Two sets of samples were prepared. One contained only NDs/BSA conjugates. The other was Fe-NDs/BSA conjugates. Both sets were prepared at a concentration of 10 mg/ml. After sample injection, mouse behavior remained normal. 
Conclusion
This paper demonstrates the in vivo enhancement of contrast through the injection of iron embedded magnetic NDs in images obtained using a typical commercial MRI scanner. This is the first research work on in vivo MRI contrast enhancement induced entirely by NDs. iron embedded magnetic NDs have considerable potential in imaging, targeted cancer therapy, and localized treatment all at the same time. Eventually, we hope that this new material, iron embedded magnetic NDs, will create or pave the way to cutting-edge new research topics which will help consolidate the study of prosperous NDs.
Methods

Fabrication of Iron embedded magnetic nanodiamonds.
ND powder (average 100nm in diameter) from Microdiamant Co. was first dissolved in DI water. The solution was then applied onto an oxidized silicon wafer and dried.
The wafer was iron-ion implanted with an energy 150 keV and dose 5x10 15 atoms/cm 2 .
The methods to remove the implanted NDs from the silicon wafer and to collect the iron embedded magnetic NDs have been described in our previous paper 23 .
Preparation of Fe-NDs/BSA conjugates and NDs/BSA conjugates.
Both Fe-NDs and NDs were purified and carboxylated to remove the surface graphite fractions and impurities with similar previously described methods 28 . The as received
NDs and Fe-NDs were treated with a mixture solution of H2SO4 and HNO3 (volume ratio 9:1) at room temperature for 24 hours respectively. After reactions, the solutions were centrifuged to get purified Fe-NDs and NDs. Purified Fe-NDs and NDs were added into the 0.1 M NaOH solution at 90 °C for 2 hours and next 0.1 M HCl solution at 90 °C for 2 hours respectively. After reactions, the solutions were centrifuged to get carboxylated Fe-NDs and NDs. Both of them were washed many times with DI water to remove free acid. After drying process, 10 mg of carboxylated Fe-NDs and NDs were mixed together with 50 mg BSA powder from Sigma-Aldrich in 2 ml PBS respectively.
After thorough mixing, the solutions were centrifuged and the sediment was washed several times to get Fe-NDs/BSA conjugates and NDs/BSA conjugates.
FTIR measurement.
To confirm the attachment of BSA, three samples, pure BSA, Fe-NDs/BSA conjugates and NDs/BSA conjugates were coated onto the silicon wafers and the absorbance of each samples were measured using a fourier transform infrared spectrometer (Bruker IFS66V/S). It is worth noting that silicon has no absorption within the measured range.
Particle size distribution and Zeta potential measurement
To understand the effect of the BSA attachment, four samples, Fe-NDs, NDs, FeNDs/BSA conjugates and NDs/BSA conjugates, were dispersed in PBS with concentration 1 mg/ml. The particle size distribution and Zeta potential of all samples were measured using a Zetasizer Nano ZS from Malvern Instruments. Images are shown pre, a day and 5 days after injection. Negative contrast enhancement was observed at Fe-NDs injected mouse after imaging processing. 
In vivo
